Randomized trial of nicotine replacement therapy ( NRT) , bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice
Open Access
- 17 July 2013
- Vol. 108 (12) , 2193-2201
Abstract
Background and aims Bupropion was introduced for smoking cessation following a pivotal trial showing that it gave improved efficacy over the nicotine patch and also suggesting combination treatment was beneficial. We tested in clinical practice for an effectiveness difference between bupropion and nicotine replacement therapy (NRT), whether the combination improves effectiveness and whether either treatment might be more beneficial for certain subgroups of smokers. Design Open‐label randomized controlled trial with 6‐month follow‐up. Setting Four UK National Health Service (NHS) smoking cessation clinics. Participants Smokers (n = 1071) received seven weekly behavioural support sessions and were randomized to an NRT product of their choice (n = 418), bupropion (n = 409) or NRT plus bupropion (n = 244). Measures The primary outcome was self‐reported cessation over 6 months, with biochemical verification at 1 and 6 months. Also measured were baseline demographics, health history, smoking characteristics and unwanted events during treatment. Findings Abstinence rates for bupropion (27.9%) and NRT (24.2%) were not significantly different (odds ratio = 1.21, 95% confidence interval = 0.883–1.67), and the combination rate (24.2%) was similar to that for either treatment alone. There was some evidence that the relative effectiveness of bupropion and NRT differed according to depression (χ2 = 2.86, P = 0.091), with bupropion appearing more beneficial than NRT in those with a history of depression (29.8 versus 18.5%). Several unwanted symptoms were more common with bupropion. Conclusion There is no difference in smoking cessation effectiveness among bupropion, nicotine replacement therapy and their combination when used with behavioural support in clinical practice. There is some evidence that bupropion is more beneficial than nicotine replacement therapy for smokers with a history of depression.Keywords
Funding Information
- Research Councils UK
This publication has 21 references indexed in Scilit:
- Nicotine receptor partial agonists for smoking cessation2010
- Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research DatabaseBMJ, 2009
- A Placebo-Controlled Trial of Bupropion Combined with Nicotine Patch for Smoking Cessation in SchizophreniaBiological Psychiatry, 2008
- Bupropion and nicotine patch as smoking cessation aids in alcoholicsAlcohol, 2007
- A 12-Week Double-Blind, Placebo-Controlled Study of Bupropion SR Added to High-Dose Dual Nicotine Replacement Therapy for Smoking Cessation or Reduction in SchizophreniaJournal of Clinical Psychopharmacology, 2007
- A randomized trial of smoking cessation. Medication versus motivationSaudi Medical Journal, 2007
- Outcome criteria in smoking cessation trials: proposal for a common standardAddiction, 2005
- Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depressionJournal of General Internal Medicine, 2004
- [Effect of treatment for nicotine dependence in patients with COPD].2003
- The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized TrialsJAMA, 2001